PE20050584A1 - Composicion y metodo para mejorar la biodisponibilidad - Google Patents
Composicion y metodo para mejorar la biodisponibilidadInfo
- Publication number
- PE20050584A1 PE20050584A1 PE2004001132A PE2004001132A PE20050584A1 PE 20050584 A1 PE20050584 A1 PE 20050584A1 PE 2004001132 A PE2004001132 A PE 2004001132A PE 2004001132 A PE2004001132 A PE 2004001132A PE 20050584 A1 PE20050584 A1 PE 20050584A1
- Authority
- PE
- Peru
- Prior art keywords
- cellulose
- carrier
- agent
- polymer
- porous particle
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 3
- 239000003795 chemical substances by application Substances 0.000 abstract 4
- 239000002245 particle Substances 0.000 abstract 4
- -1 ITROCONAZOLE Chemical compound 0.000 abstract 2
- 230000009286 beneficial effect Effects 0.000 abstract 2
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 abstract 2
- 229920000642 polymer Polymers 0.000 abstract 2
- SUBDBMMJDZJVOS-UHFFFAOYSA-N 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole Chemical compound N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 abstract 1
- 229920000896 Ethulose Polymers 0.000 abstract 1
- 235000010469 Glycine max Nutrition 0.000 abstract 1
- 244000068988 Glycine max Species 0.000 abstract 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 abstract 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 abstract 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 abstract 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 abstract 1
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 abstract 1
- 229910019142 PO4 Inorganic materials 0.000 abstract 1
- CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical compound N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 abstract 1
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 abstract 1
- 239000001913 cellulose Substances 0.000 abstract 1
- 229920002678 cellulose Polymers 0.000 abstract 1
- 235000010980 cellulose Nutrition 0.000 abstract 1
- 229960003405 ciprofloxacin Drugs 0.000 abstract 1
- 229960002626 clarithromycin Drugs 0.000 abstract 1
- AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 abstract 1
- JAUGGEIKQIHSMF-UHFFFAOYSA-N dialuminum;dimagnesium;dioxido(oxo)silane;oxygen(2-);hydrate Chemical group O.[O-2].[O-2].[Mg+2].[Mg+2].[Al+3].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O.[O-][Si]([O-])=O JAUGGEIKQIHSMF-UHFFFAOYSA-N 0.000 abstract 1
- 239000000835 fiber Substances 0.000 abstract 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 abstract 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 abstract 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 abstract 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 abstract 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 abstract 1
- 229960004844 lovastatin Drugs 0.000 abstract 1
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 abstract 1
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 abstract 1
- 229960004296 megestrol acetate Drugs 0.000 abstract 1
- RQZAXGRLVPAYTJ-GQFGMJRRSA-N megestrol acetate Chemical compound C1=C(C)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 RQZAXGRLVPAYTJ-GQFGMJRRSA-N 0.000 abstract 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 abstract 1
- 239000008108 microcrystalline cellulose Substances 0.000 abstract 1
- 229940016286 microcrystalline cellulose Drugs 0.000 abstract 1
- 229960000381 omeprazole Drugs 0.000 abstract 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 abstract 1
- 239000010452 phosphate Substances 0.000 abstract 1
- 229960002855 simvastatin Drugs 0.000 abstract 1
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 abstract 1
- 239000011734 sodium Substances 0.000 abstract 1
- 229910052708 sodium Inorganic materials 0.000 abstract 1
- 239000002904 solvent Substances 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
- 229920003169 water-soluble polymer Polymers 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Communicable Diseases (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
SE REFIERE A UNA UNIDAD PARA ADMINISTRAR UN AGENTE BENEFICIOSO CON SOLUBILIDAD BAJA, QUE COMPRENDE : UN PORTADOR DE PARTICULA POROSA QUE SE CONTACTA CON UNA MEZCLA QUE COMPRENDE AL AGENTE BENEFICIOSO Y UN POLIMERO SOLUBLE DE AGUA. EL PORTADOR DE PARTICULA POROSA ES SELECCIONADO DE MAGNESIO ALUMINOMETASILICATO, FOSFATO CALCICO DIBASICO ANHIDRO, CELULOSA MICROCRISTALINA, CARBOXIMETIL CELULOSA SODICA DEGRADADA, LA FIBRA DE CASCARA DE SOYA Y DIOXIDO DE SILICIO AGLOMERADO. EL PORTADOR DE PARTICULA POROSA ESTA PRESENTE EN UN RANGO DE 20 % A 99 % POR EL PESO DE LA UNIDAD. EL AGENTE SE ENCUENTRA PRESENTE EN UN RANGO DE 20mg A 250mg SELECCIONADO DE ACETATO DE MEGESTROL, CIPROFLOXACINO, ITROCONAZOL, LOVASTATIN, SIMVASTATINA, OMEPRAZOL, FENITOINA, CARVENDILOL, CLARITROMICINA, DICLOFENACO, ENTRE OTROS. EL POLIMERO SE SELECCIONA DE ETIL(HIDROXIETIL)CELULOSA, HIDROXIPROPIL METILCELULOSA, HIDROXIETIL CELULOSA, ENTRE OTROS. SE REFIERE TAMBIEN A UN METODO PARA PREPARAR LA COMPOSICION QUE COMPRENDE PROPORCIONAR EL PORTADOR DE PARTICULAS POROSAS; PROPORCIONAR UNA SOLUCION QUE COMPRENDE UN SOLVENTE, EL AGENTE, UN POLIMERO SOLUBLE EN AGUA Y APLICAR LA SOLUCION AL PORTADOR
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US52342103P | 2003-11-19 | 2003-11-19 | |
| US10/984,401 US20050181049A1 (en) | 2003-11-19 | 2004-11-09 | Composition and method for enhancing bioavailability |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20050584A1 true PE20050584A1 (es) | 2005-08-15 |
Family
ID=34636467
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2004001132A PE20050584A1 (es) | 2003-11-19 | 2004-11-18 | Composicion y metodo para mejorar la biodisponibilidad |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20050181049A1 (es) |
| EP (1) | EP1684726A4 (es) |
| JP (1) | JP2007511608A (es) |
| KR (1) | KR20060109934A (es) |
| AR (1) | AR048017A1 (es) |
| AU (1) | AU2004292415A1 (es) |
| CA (1) | CA2546618A1 (es) |
| IL (1) | IL175647A0 (es) |
| MX (1) | MXPA06005630A (es) |
| NO (1) | NO20062860L (es) |
| PE (1) | PE20050584A1 (es) |
| TW (1) | TW200529884A (es) |
| WO (1) | WO2005051358A1 (es) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9808052D0 (en) | 1998-04-17 | 1998-06-17 | Secr Defence | Implants for administering substances and methods of producing implants |
| PT1617832E (pt) | 2003-04-29 | 2008-06-19 | Orexigen Therapeutics Inc | Composições com efeito na perda de peso |
| JP4782695B2 (ja) * | 2004-10-25 | 2011-09-28 | 日本たばこ産業株式会社 | 溶解性及び安定性の改善された固形製剤及びその製造方法 |
| AU2005297923B2 (en) * | 2004-10-25 | 2010-12-23 | Japan Tobacco Inc. | Solid medicinal preparation improved in solubility and stability and process for producing the same |
| WO2006050221A2 (en) | 2004-10-29 | 2006-05-11 | The Regents Of The University Of California | Porous photonic crystals for drug delivery to the eye |
| US20070009589A1 (en) * | 2005-07-07 | 2007-01-11 | Kandarapu Raghupathi | Extended release compositions |
| EP1933811A2 (en) * | 2005-09-30 | 2008-06-25 | Alza Corporation | Banded controlled release nanoparticle active agent formulation dosage forms and methods |
| MX337422B (es) | 2005-11-22 | 2016-03-04 | Orexigen Therapeutics Inc | Composiciones y metodos para incrementar la sencibilidad a la insulina. |
| EP1954241B1 (en) * | 2005-11-28 | 2012-02-29 | Orexigen Therapeutics, Inc. | Sustained-release formulation of zonisamide |
| US20090186081A1 (en) * | 2006-01-05 | 2009-07-23 | Lifecycle Pharma A/S | Disintegrating Loadable Tablets |
| US8916195B2 (en) | 2006-06-05 | 2014-12-23 | Orexigen Therapeutics, Inc. | Sustained release formulation of naltrexone |
| TWI504419B (zh) | 2006-11-09 | 2015-10-21 | Orexigen Therapeutics Inc | 層狀醫藥調配物 |
| JP2010508997A (ja) | 2006-11-09 | 2010-03-25 | オレキシジェン・セラピューティクス・インコーポレーテッド | 減量薬を投与するための方法 |
| DE102006054638B4 (de) * | 2006-11-16 | 2014-12-04 | Laburnum Gmbh | Pharmazeutische Einzeldosisform |
| EP2500015A1 (en) | 2006-12-05 | 2012-09-19 | Landec Corporation | Delivery of drugs |
| US8399007B2 (en) | 2006-12-05 | 2013-03-19 | Landec Corporation | Method for formulating a controlled-release pharmaceutical formulation |
| GB0709541D0 (en) * | 2007-05-17 | 2007-06-27 | Jagotec Ag | Pharmaceutical excipient |
| FR2918277B1 (fr) * | 2007-07-06 | 2012-10-05 | Coretecholding | Nouveau procede de production de formes pharmaceutiques seches hydrodispersibles et les compositions hydrodispersibles ainsi obtenues |
| KR20160021307A (ko) * | 2007-07-10 | 2016-02-24 | 더 리전트 오브 더 유니버시티 오브 캘리포니아 | 선택된 조직에 조성물을 전달하는 물질 및 방법 |
| US20090035370A1 (en) * | 2007-08-02 | 2009-02-05 | Drugtech Corporation | Dosage form and method of use |
| US8114883B2 (en) | 2007-12-04 | 2012-02-14 | Landec Corporation | Polymer formulations for delivery of bioactive materials |
| CA2725930A1 (en) | 2008-05-30 | 2009-12-30 | Orexigen Therapeutics, Inc. | Methods for treating visceral fat conditions |
| EP2135601A1 (en) * | 2008-06-20 | 2009-12-23 | Capsulution Nanoscience AG | Stabilization of amorphous drugs using sponge-like carrier matrices |
| PL2403482T3 (pl) | 2009-03-04 | 2018-06-29 | Emplicure Ab | Preparat odporny na nadużywanie |
| CN105476951A (zh) | 2009-05-04 | 2016-04-13 | 普西维达公司 | 多孔硅药物洗脱颗粒 |
| DK2427177T3 (en) | 2009-05-08 | 2018-06-18 | Emplicure Ab | Composition for prolonged drug delivery comprising geopolymer binder |
| WO2010144755A2 (en) * | 2009-06-11 | 2010-12-16 | Landec Corporation | Compositions and methods for delivery of materials |
| EP3659604A1 (en) | 2010-01-11 | 2020-06-03 | Nalpropion Pharmaceuticals, Inc. | Methods of providing weight loss therapy in patients with major depression |
| KR20140003405A (ko) | 2010-09-07 | 2014-01-09 | 오렉쏘 에이비 | 경피 약물 투여 장치 |
| CA2816576C (en) | 2010-11-01 | 2020-06-02 | Psivida Us, Inc. | Bioerodible silicon-based devices for delivery of therapeutic agents |
| US9394369B2 (en) | 2011-01-03 | 2016-07-19 | The Regents Of The University Of California | Luminescent porous silicon nanoparticles for targeted delivery and immunization |
| MX369990B (es) | 2012-06-06 | 2019-11-27 | Orexigen Therapeutics Inc | Composiciones de liberación sostenida de naltrexona y bupropión para usarse en el tratamiento de sobrepeso y obesidad. |
| US8652527B1 (en) | 2013-03-13 | 2014-02-18 | Upsher-Smith Laboratories, Inc | Extended-release topiramate capsules |
| US9101545B2 (en) | 2013-03-15 | 2015-08-11 | Upsher-Smith Laboratories, Inc. | Extended-release topiramate capsules |
| EP2968571A4 (en) | 2013-03-15 | 2016-09-07 | Psivida Inc | BIODEGRADABLE SILICONE BASED COMPOSITIONS FOR THE DELIVERY OF THERAPEUTIC AGENTS |
| CN114533898B (zh) | 2015-07-09 | 2025-07-01 | 加利福尼亚大学董事会 | 融合脂质体包被的多孔硅纳米颗粒 |
| CN118955352A (zh) | 2017-12-05 | 2024-11-15 | 赛诺维信制药公司 | 晶体形式及其制备方法 |
| KR20200110648A (ko) | 2017-12-05 | 2020-09-24 | 선오비온 파마슈티컬스 인코포레이티드 | 비라세믹 혼합물 및 이의 용도 |
| MX2021014774A (es) | 2019-06-04 | 2022-02-03 | Sunovion Pharmaceuticals Inc | Formulaciones de liberacion modificada y usos de las mismas. |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI940028A7 (fi) * | 1991-07-05 | 1994-02-25 | Univ Rochester | Kaasukuplia sisäänsä sulkevia ultrapieniä aggregoitumattomia huokoisia hiukkasia |
| JP2700141B2 (ja) * | 1993-09-17 | 1998-01-19 | 富士化学工業株式会社 | リン酸水素カルシウム及びその製法並びにそれを用いた賦形剤 |
| US5633011A (en) * | 1994-08-04 | 1997-05-27 | Alza Corporation | Progesterone replacement therapy |
| US5885616A (en) * | 1997-08-18 | 1999-03-23 | Impax Pharmaceuticals, Inc. | Sustained release drug delivery system suitable for oral administration |
| SE512958C2 (sv) * | 1998-04-30 | 2000-06-12 | Triple Crown Ab | Kolesterolsänkande komposition innehållande beta-sitosterol och/eller beta-sitostanol samt förfarande för dess framställning |
| JP4027535B2 (ja) * | 1998-05-26 | 2007-12-26 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 脂溶性薬物を含有した粉末 |
| US6174547B1 (en) * | 1999-07-14 | 2001-01-16 | Alza Corporation | Dosage form comprising liquid formulation |
| CA2354472C (en) * | 1998-12-17 | 2009-02-24 | Alza Corporation | Conversion of liquid filled gelatin capsules into controlled release systems by multiple coatings |
| US6342249B1 (en) * | 1998-12-23 | 2002-01-29 | Alza Corporation | Controlled release liquid active agent formulation dosage forms |
| US6395300B1 (en) * | 1999-05-27 | 2002-05-28 | Acusphere, Inc. | Porous drug matrices and methods of manufacture thereof |
| US6793934B1 (en) * | 1999-12-08 | 2004-09-21 | Shire Laboratories, Inc. | Solid oral dosage form |
| US6720003B2 (en) * | 2001-02-16 | 2004-04-13 | Andrx Corporation | Serotonin reuptake inhibitor formulations |
| RU2330642C2 (ru) * | 2001-07-06 | 2008-08-10 | Лайфсайкл Фарма А/С | Регулируемая агломерация |
| US20050175689A1 (en) * | 2003-10-27 | 2005-08-11 | Yamanouchi Pharmaceutical Co., Ltd. | Coated fine particles containing drug for intrabuccally fast disintegrating tablet |
-
2004
- 2004-11-09 US US10/984,401 patent/US20050181049A1/en not_active Abandoned
- 2004-11-12 CA CA002546618A patent/CA2546618A1/en not_active Abandoned
- 2004-11-12 EP EP04810907A patent/EP1684726A4/en not_active Withdrawn
- 2004-11-12 KR KR1020067011779A patent/KR20060109934A/ko not_active Withdrawn
- 2004-11-12 WO PCT/US2004/037927 patent/WO2005051358A1/en not_active Ceased
- 2004-11-12 AU AU2004292415A patent/AU2004292415A1/en not_active Abandoned
- 2004-11-12 JP JP2006541279A patent/JP2007511608A/ja not_active Withdrawn
- 2004-11-12 MX MXPA06005630A patent/MXPA06005630A/es unknown
- 2004-11-18 TW TW093135330A patent/TW200529884A/zh unknown
- 2004-11-18 PE PE2004001132A patent/PE20050584A1/es not_active Application Discontinuation
- 2004-11-19 AR ARP040104283A patent/AR048017A1/es not_active Application Discontinuation
-
2006
- 2006-05-15 IL IL175647A patent/IL175647A0/en unknown
- 2006-06-19 NO NO20062860A patent/NO20062860L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| IL175647A0 (en) | 2006-09-05 |
| TW200529884A (en) | 2005-09-16 |
| MXPA06005630A (es) | 2006-12-14 |
| EP1684726A4 (en) | 2007-10-03 |
| AU2004292415A1 (en) | 2005-06-09 |
| US20050181049A1 (en) | 2005-08-18 |
| NO20062860L (no) | 2006-08-17 |
| WO2005051358A8 (en) | 2005-07-21 |
| WO2005051358A1 (en) | 2005-06-09 |
| JP2007511608A (ja) | 2007-05-10 |
| AR048017A1 (es) | 2006-03-22 |
| KR20060109934A (ko) | 2006-10-23 |
| EP1684726A1 (en) | 2006-08-02 |
| CA2546618A1 (en) | 2005-06-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20050584A1 (es) | Composicion y metodo para mejorar la biodisponibilidad | |
| PE20080249A1 (es) | Composicion farmaceutica que contiene pioglitazona | |
| ES2625145T3 (es) | Aplicación tópica y formulación de eritropoyetina para cicatrizar heridas cutáneas | |
| AR039379A1 (es) | Matriz para la liberacion sostenida, invariable e independiente de compuestos activos | |
| RU2013122395A (ru) | Фармацевтические составы для местного применения, содержащие низкую концентрацию бензоилпероксида в суспензии в воде и смешивающимся с водой органическом растворителе | |
| JP4595058B2 (ja) | 二酸化炭素外用剤調製用組成物 | |
| MA29619B1 (fr) | Derive de 1,1 -dioxyde de 1,4-benzothiazepine, procede de preparation, medicaments comprenant ce compose, et utilisation de celui-ci comme hypolipidemiant | |
| NZ610701A (en) | Once daily formulation of lacosamide | |
| WO2009082459A3 (en) | Anti-aging composition containing resveratrol and method of administration | |
| MY141939A (en) | Pyridazine derivatives and their use as therapeutic agents | |
| PE20010982A1 (es) | Composicion estable para dosis oral de liberacion extendida | |
| PE20100265A1 (es) | Nuevas composiciones farmaceuticas que comprenden levetiracetam y proceso para su preparacion | |
| AR039955A1 (es) | Preparados con principio activo en forma de pelicula con mejora de la estabilidad quimica, y procedimiento para su fabricacion | |
| BR0007360A (pt) | Composição de liberação controlada | |
| ES2282062T1 (es) | Composicion farmaceutica que contiene irbesartan. | |
| BR0307278A (pt) | Formulação oral de liberação imediata, e, método para preparar uma formulação | |
| EP2364692A3 (fr) | Compositions comprenant au moins un derive de l'acide naphtoïque, du peroxyde de benzoyle et au moins un agent filmogene, leurs procedes de preparation, et leurs utilisations | |
| JPS59157009A (ja) | メラニン生成抑制外用剤 | |
| MXPA05013390A (es) | Composicion para el cuidado de la piel que comprende un agente aclarador de la piel. | |
| WO2006118948A3 (en) | Therapeutic compositions | |
| AR044861A1 (es) | Una composicion para pelicula consumible via oral para suministrar agentes antiplaca y refrescantes del aliento | |
| JP4599543B2 (ja) | 二酸化炭素外用ゲル調製用組成物と二酸化炭素外用ゲル | |
| CO5640120A2 (es) | Formulacion y metodods para el tratamiento de trombocitemia | |
| AR006345A1 (es) | Una composicion farmaceutica para administracion oral que comprende un inhibidor de proteasa del vih y un derivado de tocoferol soluble en agua, y un metodo para preparar dicha composicion. | |
| PE20011113A1 (es) | Sistema de administracion oral controlada para la ingestion diaria de ciprofloxacina |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |